ligands acting on targets

(S)-Carvedilol, the S-enantiomer of Carvedilol, is a non-selective β/α-1 blocker. (S)-Carvedilol exerts protection against the vascular or cardiac toxicity of Doxorubicin (DOX)In VitroThe β-receptor blocking activity of (S)-Carvedilol is about 100

(S)-Carvedilol, the S-enantiomer of Carvedilol, is a non-selective β/α-1 blocker. (S)-Carvedilol exerts protection against the vascular or cardiac toxicity of Doxorubicin (DOX)In VitroThe β-receptor blocking activity of (S)-Carvedilol is about 100

(S)-Carvedilol, the S-enantiomer of Carvedilol, is a non-selective β/α-1 blocker. (S)-Carvedilol exerts protection against the vascular or cardiac toxicity of Doxorubicin (DOX)In VitroThe β-receptor blocking activity of (S)-Carvedilol is about 100

(S)-Ceralasertib ((S)-AZD6738) is extracted from patent WO2011154737A1, Compound II, exhibits an IC 50 of 2.578 nM.(S)-Ceralasertib is a potent and selective sulfoximine morpholinopyrimidine ATR inhibitor with excellent preclinical physicochemical

(S)-Ceralasertib ((S)-AZD6738) is extracted from patent WO2011154737A1, Compound II, exhibits an IC 50 of 2.578 nM.(S)-Ceralasertib is a potent and selective sulfoximine morpholinopyrimidine ATR inhibitor with excellent preclinical physicochemical

(S)-Ceralasertib ((S)-AZD6738) is extracted from patent WO2011154737A1, Compound II, exhibits an IC 50 of 2.578 nM.(S)-Ceralasertib is a potent and selective sulfoximine morpholinopyrimidine ATR inhibitor with excellent preclinical physicochemical

(S)-Ceralasertib ((S)-AZD6738) is extracted from patent WO2011154737A1, Compound II, exhibits an IC 50 of 2.578 nM.(S)-Ceralasertib is a potent and selective sulfoximine morpholinopyrimidine ATR inhibitor with excellent preclinical physicochemical

(S)-Ceralasertib ((S)-AZD6738) is extracted from patent WO2011154737A1, Compound II, exhibits an IC 50 of 2.578 nM.(S)-Ceralasertib is a potent and selective sulfoximine morpholinopyrimidine ATR inhibitor with excellent preclinical physicochemical

(S)-cetirizine.

(S)-cetirizine.

(S)-Cetirizine Dihydrochloride is a nonsedating type histamine H1-receptor antagonist. This is a major metabolite of Hydroxyzine where pharmacological activity resides primarily in the (R)-isomer. It is also an antihystaminic.

(S)-Cetirizine Dihydrochloride is a nonsedating type histamine H1-receptor antagonist. This is a major metabolite of Hydroxyzine where pharmacological activity resides primarily in the (R)-isomer. It is also an antihystaminic.